Los Angeles, Calif., April 8, 2016 – Diversis Capital, LLC, a Los Angeles-based private equity firm focused on acquiring and growing small- and middle-market companies, today announced that it has acquired the majority of the assets of Caligor Rx, Inc. Based in Secaucus, New Jersey with an additional facility in Dartford, UK, Caligor provides services that enable pharmaceutical and biotechnology companies to maximize the value of their clinical supply chain investments. Financial terms of the transaction were not disclosed.
From its roots as a pharmacy started in 1919, Caligor has established itself as a leader in sourcing and distributing comparator drugs for clinical trials worldwide. Complementing its comparator business, Caligor provides regulatory expertise and strategic services for setting up Global Access Programs (GAP). These programs supply investigational medicines to individual patients, and groups of patients, who have life-threatening conditions but lack access to clinical trials or approved therapeutic alternatives. Caligor’s leadership team has implemented and managed these programs in more than 70 countries.
“Caligor has a strong, successful track record of delivering strategic clinical trial supply and logistics services to the pharmaceutical and biotechnology industries,” said Kevin Ma, a managing director for Diversis Capital. “We are excited about driving the next stage of Caligor’s growth and shaping its long-term strategy. We will provide additional resources and operational expertise to expand the Company’s comparator and GAP offerings, broaden the reach of its businesses to new geographic regions, enhance its logistics capabilities and build on its leadership position.”
Diversis plans to invest heavily in Caligor to enhance its sales and marketing, logistics capabilities, distribution infrastructure and service offerings. These investments will include a new warehouse in Dartford, UK. Slated to open in late 2016, the warehouse will have about five times more space than the current UK facility.
“We are excited about the opportunity to provide Caligor’s current and future clients with an enhanced array of services to further optimize their clinical programs and bring new drugs to market more efficiently,” said Ron Nayot, a managing director for Diversis Capital.
Tammy Bishop, previously managing director of Caligor, becomes CEO of the Company. “Our entire global team is delighted to become part of the Diversis portfolio,” she said. “This acquisition underscores a strong belief in Caligor’s long-term growth. Diversis’ commitment to invest significant resources in Caligor – in our people, systems and capabilities – ultimately benefits clients as well as employees.”
About Caligor Rx
Caligor is a global company that manages the regulatory, logistics and supply chain challenges of sourcing, storing and distributing investigational drugs for comparator clinical trials and unlicensed medicines for expanded access programs. The Company serves pharmaceutical and biotechnology companies from facilities in Secaucus, New Jersey and Dartford, UK, as well as depot locations worldwide. Caligor supports comparator studies as well as programs for patients who have life-threatening conditions but lack access to clinical trials or approved therapeutic alternatives. More information is available at http://caligorrx.com/.
About Diversis Capital
Founded in 2013, Diversis Capital, LLC is a North American private equity firm with a focus on carve-outs, standalone deals and special situations in the lower and middle markets that require both sharp financial acumen and operational expertise to reach success. The tight-knit team of professionals has experience working on complex transactions and leveraging deep hands-on operational expertise to help companies and their management teams achieve full potential. Diversis, which was founded by Managing Directors Ron Nayot and Kevin Ma along with Marc Luzzatto, the firm’s Chairman, is currently in full acquisition mode with a goal of executing several transactions annually.
Sharon Merrill Associates, Inc.
You must be logged in to post a comment.